Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04626791
Title Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Academic and Community Cancer Research United
Indications

mantle cell lymphoma

Therapies

Acalabrutinib + Cytarabine + Rituximab Hyaluronidase

Acalabrutinib + Cytarabine + Rituximab

Acalabrutinib + Bortezomib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab

Acalabrutinib + Bortezomib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Hyaluronidase

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.